Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERIES: Sacituzumab Govitecan After T-DXd in ER+/HER2 Low/Ultra Low Metastatic Breast Cancer
NCT06263543Phase 2Recruiting
- Sponsor
- Reshma L. Mahtani
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in breast cancer, sponsored by Reshma L. Mahtani. Primary endpoint: Overall Response Rate at 24 months. Started Jun 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06263543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263543.